Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Prior treatment

• Participants who are or have previously been on Xultophy® therapy.
• Previous participation in this study. Participation is defined as having given informed consent in this study.

Other illness

• Known or suspected hypersensitivity to Xultophy® (the active substance or any of the excipients).

Other

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

• The decision to initiate treatment with commercially available Xultophy® has been made by the participant/Legally Acceptable Representative (LAR) and the study doctor before and independently from the decision to include the participant in this study.
• Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• Male or female, age 19 years or older at the time of signing informed consent form.
• Participants diagnosed (clinically) with T2DM and who is scheduled to start treatment with Xultophy® based on the clinical judgment of their treating physician as specified in the approved Korean-Prescribing information (local label).